{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 59,
  "pageCount": 61,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a combination of expert testimonials and a comparative table of clinical trials to validate the outpatient administration model.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/59",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-59",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "01 Outpatient Tecvayli “safe and feasible”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15021a42-54d7-4b7f-b4b5-e9b8e17bf0a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "02 Administration of Tecvayli will “not be the same as in MajesTEC-1”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74bcb301-c11a-42ef-ba1c-7b6ceaf2109c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.38,
        "y": 0.45
      },
      "kind": "quote",
      "text": "teclistamab has been approved based on the MajesTEC-1 study, where it was given a certain way. I'm convinced that's not how we'll be using teclistamab in the future",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f6d8d17-1234-48df-b03d-06e7c1ae7a83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.42,
        "y": 0.2
      },
      "kind": "quote",
      "text": "We have treated over 20 patients with our outpatient [Teclistamab dosing] program so far... in conclusion outpatient Teclistamab, step up administration model with close monitoring is safe and feasible...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4481076e-6d40-45a7-a5a9-72600fe9eb9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.45
      },
      "kind": "quote",
      "text": "We learned how to give patients daratumumab [Darzalex]. Initially, there were a lot of infusion reactions. Now everybody feels very comfortable and we give it to patients all the time",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa608c71-be3f-4dab-a429-c94c45a0b95a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.2,
        "y": 0.7
      },
      "kind": "table",
      "text": "Clinical trial comparison table for NCT05972135 and NCT06015542",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50a4200a-523a-4260-88dc-b20a4870a809",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "BCMA Bispecific Antibodies (Tecvayli, Elrexfio) Are Currently Being Investigated As An Outpatient Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42d6927d-5c61-4ad4-837e-3993dfc80b36",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "98450710-3baf-4c90-b0cc-3416b7fe9ddd",
      "evidence": "Combines expert testimonials with clinical trial data to support a thesis.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 61,
      "from": 18,
      "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}